Complete Transparency: Recent FDA Decisions Renew Calls For Making Complete Response Letters Public
This article was originally published in RPM Report
Executive Summary
Three major stakeholders in drug development—regulators, industry, and investors—say they want or could live with FDA complete response letters being made public. Why aren’t they, and will it happen in the current political environment?
You may also be interested in...
Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public
FDA's transparency initiative is starting to take shape. While many industry executives see the value in making more information available to the public, one idea makes them nervous: publicizing the letters FDA sends when it declines to approve a new drug or biologic. Top FDA officials already support making "complete response" letters public, and the Commissioner's office is open to the idea. How should industry prepare?
The FDA Roundtable Part I: The Regulators' View of Drug Development
Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.